Payment overview · 2025
General Payments
$88.91
4 reported records · 3 companies
Healthcare provider profile · identity verified
Douglas Albin Magnuson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GREELEY, CO · NPI 1104891027
Verified facts
What the public records show
CMS Open Payments records show Douglas Albin Magnuson, MD received $88.91 in general payments during 2025 across 4 reported records.
ABBVIE INC. accounted for 62.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Shingrix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.62 | 62.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.12 | 19.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.17 | 18.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $88.91 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $55.62 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 25 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
25 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 286 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 248 | 68 |
| Losartan Potassium | Losartan Potassium | 190 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 186 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 176 | 46 |
| Omeprazole | Omeprazole | 164 | 43 |
| Prednisone | Prednisone | 153 | 113 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 30 |
| Meloxicam | Meloxicam | 113 | 42 |
| Tramadol Hcl | Tramadol Hcl | 112 | 32 |
| Metformin Hcl | Metformin Hcl | 108 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 28 |
| Simvastatin | Simvastatin | 90 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 79 | 19 |
| Gabapentin | Gabapentin | 70 | 22 |
| Lorazepam | Lorazepam | 70 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 60 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 17 |
| Famotidine | Famotidine | 51 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 50 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 49 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | 14 |
| Baclofen | Baclofen | 43 | 22 |
| Sertraline Hcl | Sertraline Hcl | 43 | 12 |
| Warfarin Sodium | Warfarin Sodium | 43 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 14 |
| Alprazolam | Alprazolam | 37 | suppressed |
| Furosemide | Furosemide | 37 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 35 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 29 |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Nabumetone | Nabumetone | 30 | 11 |
| Eliquis | Apixaban | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 29 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Allopurinol | Allopurinol | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 25 | 20 |
| Clonazepam | Clonazepam | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 22 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 21 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levoxyl | Levothyroxine Sodium | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 11 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Cabergoline | Cabergoline | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $88.91 · 4 records | ABBVIE INC. | AREXVY, OTEZLA, QULIPTA, REPATHA, SHINGRIX, UBRELVY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error